Search

Prof Robert MacLaren, University of Oxford - £119,610 (co-funded with Retina UK)

New research into a gene editing therapy for those with Stargardt disease is being undertaken at Oxford University. In Stargardt disease, a mutation in the ABCA4 gene means that the ABCA4 protein produced from the gene is faulty and this leads to sight loss. The project aims to develop a gene therapy to ensure healthy ABCA4 protein is made and further damage is prevented.

Dr Keziah Latham, Anglia Ruskin University - £99,976

This work will compare different low vision aids (LVA) and their use, cost-effectiveness and impact on quality of life. The aim is to enable people to make better decisions on what device is right for them, particularly considering the cost of some of the devices such as wearable technologies.

Dr Linda Troeberg, University of East Anglia - £99,573

Correct protein delivery is necessary for all cells to function efficiently and stay healthy. If proteins aren’t delivered to the right place or in the right amounts, this can lead to cells not functioning properly. This work is focusing on a specific protein called TIMP-3, which is believed to be involved in AMD and Sorsby Fundus Dystrophy (SFD). By understanding how TIMP-3 is delivered around tissue when in healthy and mutated forms, we can better understand the mechanism of these two macular diseases.

Dr Forbes Manson, University of Manchester - £99,672

This project aims to test whether a new form of gene editing could help those with a macular dystrophy. Current gene editing approaches are looking at fixing or changing a gene mutation, which is very fiddly and will only help a small proportion of patients with that specific mutation.

Professor David Kavanagh, Newcastle University - £98,506

This project aims to analyse different mutations in the gene CFI, which has been shown to be highly involved in age-related macular disease (AMD). Some mutations have been strongly linked to an increased risk of developing AMD, but some mutations have no effect on your risk.

Dr Cristina Martinez Fernandez, John Radcliffe Hospital, Oxford -£24,700

Cone dystrophy is often caused by genetic mutations on a single gene, RPGR (Retinitis pigmentosa GTPase regulator), leading to the loss of central vision by affecting the cone photoreceptors across the retina and around the macula. This condition can significantly impact a person’s ability to perceive color and detail, particularly in bright light conditions.

Dr Ioan Matei, Edgehill University - £24,943

Gene editing is a process by which the structure of a gene can be changed by modifying the DNA sequence. The technique used is called CRISPR Cas-9 and can be thought of as a pair of scissors that can cut out, swap around or add in parts of a gene.

Dr David Sauer, University of Oxford - £25,000

Macular health relies heavily on an amino acid called proline. It is a precursor for one of the nutrients that the retinal pigment epithelium (RPE) is responsible for supplying to the photoreceptors of the macula. Proline is transferred using a transporter protein called SIT-1.

Dr Richard Unwin, Manchester University -£23,931

Early age-related macular degeneration (AMD) is closely linked to the switching on and off of the part of the immune system called the complement system. This system is genetically influenced and plays a key role in inflammation and defending against bacterial infections.

Dr Eleni Beli, Queen’s University Belfast - £25,000

Circadian rhythms affect many processes in the eye. This research investigates the link between day length and the development of diabetic retinopathy (DR) by exposing mice to day lengths made artificially either longer or shorter than 24 hours.